ORIC News and Press, Oric Pharmaceuticals Inc. From 11/13/25

2025-11-13 16:56:07 ET More on ORIC Pharmaceuticals ORIC Pharmaceuticals, Inc. (ORIC) Pharmaceuticals, Inc. Presents at Citi's Biopharma Back to School Conference - Slideshow ORIC Pharmaceuticals, Inc. (ORIC) Pharmaceuticals, Inc. Presents At Citi's Biopharma Back To School ...

Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety Bolstered leadership team with the appointment of Kevin Brodbeck, PhD, as Chief Technical Officer to further su...

Efficacy data remain consistent with prior disclosure and continue to demonstrate broad and deep PSA responses, with 55% PSA50 response rate and 20% PSA90 response rate Rapid and deep ctDNA reductions were observed in 76% of patients and ctDNA clearance was observed in 59% of patients, un...

Ensysce Biosciences Inc. (ENSC) is expected to report $-0.85 for Q3 2025 IO Biotech Inc. (IOBT) is expected to report $-0.31 for Q3 2025 Lifeward Ltd. (LFWD) is expected to report $-0.14 for Q3 2025 Life360 Inc. (LIF) is expected to report $0.03 for Q3 2025 Pixelworks Inc. (PXLW) ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the publication of a peer-reviewed research...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented posters at the 2025 EORTC-NCI-AACR International ...

2025-10-17 07:01:47 ET Shares of autoimmune and oncology concern Cullinan Therapeutics, Inc. ( CGEM ) are down approximately 70% since May 2024, owing to a data vacuum from its off-the-shelf CD19xCD3 T cell engager CLN-978. The now autoimmune therapy should provide eagerly await...

2025-09-03 19:37:13 ET ORIC Pharmaceuticals, Inc. (ORIC) Pharmaceuticals, Inc. Citi's Biopharma Back to School Conference September 3, 2025 4:00 PM EDT... Read the full article on Seeking Alpha For further details see: ORIC Pharmaceuticals, Inc. (ORIC) Pharmaceuticals, Inc. ...

2025-08-12 16:53:04 ET More on ORIC Pharmaceuticals ORIC Pharmaceuticals: What It Takes To Be Best In Class ORIC Pharmaceuticals announces $125M private placement to advance cancer pipeline Seeking Alpha’s Quant Rating on ORIC Pharmaceuticals Historica...

Reported potentially best-in-class clinical efficacy and safety data from ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for the treatment of patients with mCRPC Strengthened cash position with $244 million gross proceeds from top-tier healthcare specialist investors...